arrow
C

Carlos E. de Andrea

Clínica Universidad de Navarra
H指数:30
被引数:2,934

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma

诊断时CD70过表达预示复发并支持在滤泡性淋巴瘤中进行CD19-CD70双CAR-T疗法

Blood
IF23.1
2026-01-010
OAAI
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort

病理反应新辅助评分的更新的全肿瘤指南: SITC和INMC的联合努力

2025-11-040
PRE
Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients

PD-1、LAG-3和TIM-3在肿瘤内CD8 T细胞上的表达与接受阿替利珠单抗治疗的晚期尿路上皮癌患者治疗反应的相关性:一项真实世界证据生物标志物研究

2025-08-080
OAAI
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

作者更正: 溶瘤DNX-2401病毒疗法联合pembrolizumab治疗复发性胶质母细胞瘤: 1/2期试验

2025-07-210
OA
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models

靶向纤维细胞活化蛋白α的4-1BB激动剂与放射疗法协同作用以治疗小鼠乳腺癌模型

2025-02-111
OA
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort

更新后的泛肿瘤新辅助治疗病理反应评分指南:SITC 与 INMC 联合努力

2024-09-010
PRE
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
2023-05-15113
OAAI
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer.

肿瘤反应性CD4和CD8 til的生物标志物与子宫内膜癌预后改善相关。

2022-12-2922
OAAI
Neutrophil Extracellular Traps, Local IL-8 Expression, and Cytotoxic T-Lymphocyte Response in the Lungs of Patients With Fatal COVID-19
CHEST
IF8.6
2022-11-0131
OAAI
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, INFα, and IL-1β
2022-06-3028
OA